medigraphic.com
ISSN 1527-3172 (Electronic)

2014, Number 1

<< Back Next >>

MEDICC Review 2014; 16 (1)

Platelet serotonin concentration and clinical status in alcohol withdrawal syndrome, preliminary results

Llinás CSG, Caballero MAJ, Peńalver GJC, Valdés VR

Language: English
References: 34
Page: 37-41
PDF size: 183.61 Kb.


ABSTRACT

Introduction: Alcohol withdrawal syndrome is an important problem for management of alcoholism. It is known that alcohol alters the function of neurotransmitters such as serotonin, but our review found no studies associating serotonin concentration changes with patient clinical status during detoxification. The authors hypothesized that total platelet serotonin concentration should significantly increase during alcohol detoxification.
Objetive: Assess possible association between total (endogenous and captured) platelet serotonin concentration and clinical status of patients with alcohol withdrawal syndrome, at beginning and end of detoxification with clomethiazole.
Methods: Thirty-one alcohol-dependent patients, diagnosed with alcohol withdrawal syndrome according to DSM-IV and classified in three clinical groups (18–20, 21–22 and 23–26 points) per the Clinical Institute Withdrawal Assessment for Alcohol Scale, were included in a prospective case series from May 2009 through May 2011 at the Hermanos Ameijeiras Clinical-Surgical Teaching Hospital in Cuba. Patients were predominantly male (87%), ranging in age from 22 to 57 years; 40% were white, 40% mestizo and 20% black. All had been hospitalized for detoxification in the hospital's psychiatry service. Blood samples taken were mixed with 1% EDTA and centrifuged for isolating platelets. Serotonin concentrations (endogenous and captured) were measured within 2 hours of blood collection and mean values at treatment days 1 and 12 compared by t test (p ‹ 0.05).
Results: Total serotonin concentration mean values (µg of serotonin per mg of total platelet protein) were statistically different between days 1 and 12 of treatment (1.329 ± 0.916 µg/mg vs. 2.573 ± 1.224 µg/mg; p ‹ 0.001). There was a direct association between total serotonin concentration and patient clinical classification both initially and at day 12. At day 1, the 29 patients in the group with 18–20 points had mean serotonin of 1.358 ± 0.0.94 µg/mg; one patient with 21 points had serotonin of 1.25 µg/mg; and one patient with 24 points had serotonin of 0.740 µg/mg. At day 12, 26 patients had 0–1 points, with mean serotonin 2.688 ± 1.244 µg/mg; and 5 patients had 2–8 points, with mean serotonin 1.244 ± 0.596 µg/mg. No patient had › 8 points at day 12.
Conclusions: Serotonin is a potential biomarker for initial clinical classification and outcome monitoring and could be useful to psychiatrists working with patients in this area of medical practice and research. Further studies including more patients and variables are necessary to support these preliminary results.


REFERENCES

  1. World Health Organization. Global status report on non-communicable diseases [Internet]. Geneva: World Health Organization; 2010 [cited 2013 Sep 26]. 164 p. Available from: http://www.who .int/nmh/publications/ncd_report_full_en.pdf

  2. Sánchez JF, Álvarez P, Rodríguez JJ. Psychiatric disorders associated with alcoholism: 2 year follow-up of treatment. Actas Esp Psiquiatr. 2012 May–Jun;40(3):129–35.

  3. Chen CY, Storr CL, Anthony JC. Early-onset drug use and risk for drug dependence problems. Addict Behav. 2009 Mar;34(3):319–22.

  4. Freeman WM, Vrana KE. Future prospect for biomarkers of alcohol consumption and alcoholinduced disorder. Acohol Clin Exp Res. 2010 Jun;34(6):946–54.

  5. Johnson BA. Role of serotoninergic system in the neurobiology of alcoholism. CNS Drugs. 2004;18(15):1105–18.

  6. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Ann Rev Med. 2009;60:355–66.

  7. Aguayo LG, Peoples RW, Yeh HH, Yevenes GE. GABA (A) receptors as molecular sites of ethanol action. Direct or indirect actions? Curr Top Med Chem. 2002 Aug;2(8):869–85.

  8. Bajo M, Madamba SG, Lu X, Sharkey LM, Bartfai T, Siggins GR. Receptor subtype-dependent galanin actions on γ-aminobutyric acidergic neurotransmission and ethanol responses in the central amygdala. Addict Biol. 2012 Jul;17(4):694–705.

  9. Schuckit MA. Alcohol-use disorders. Lancet. 2009 Feb 7;373(9662):492–501.

  10. Nenadic-Sviglin K, Nedic G, Nikolac M, Kozaric- Kovacic D, Stipcevic T, Muck Seler D, et al. Suicide attempt, smoking, comorbid depression, and platelet serotonin in alcohol dependence. Alcohol. 2011 May;45(3):209–16.

  11. Mukherjee S, Das SK, Vaidyanathan K, Vasudevan DM. Consequences of alcohol consumption on neurotransmitters—An overview. Curr Neurovasc Res. 2008 Nov;5(4):266–72.

  12. Lovinger DM. The role of serotonin in alcohol’s effects on the brain. Curr Separations. 1999;18(1):23–8.

  13. Hughes JR. Alcohol withdrawal seizures. Epilepsy Behav. 2009 Jun;15(2):92–7.

  14. Martín MM, Pastor I, Laso F. Farmacogenética en el tratamiento del alcoholismo. Act Farmacol Terapéutica. 2012;10(3):159–60. Spanish.

  15. Bayard M, McIntyre J, Hill KR, Woodside JJr. Alcohol withdrawal syndrome. Am Fam Physician. 2004 Mar;69(6):1443–50.

  16. Veray R, Vekaria S, Eisenberg S. Treatment of the hospitalized alcohol-dependent patient with alcohol withdrawal syndrome. Internet J Int Med [Internet]. 2009 [cited 2013 Sep 26];8(1). Available from: http://ispub.com/IJIM/8/1/6232#

  17. Reilly TM. Physiological dependence on, and symptoms of withdrawal from chlormethiazole. Brit J Psychiatry. 1976 Apr;128:375–8.

  18. Kleber HD, Weiss RD, Anton RF Jr, George TP, Greenfi eld SF, Kosten TR, et al. Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry. 2007 Apr;164(4 Suppl):5–123.

  19. Cortes C, Galindo F, Galicia S, Flores A. GABA: żdualidad funcional? Transición durante el neurodesarrollo. Rev Neurol. 2011 Jun;52(11):665– 75. Spanish.

  20. Möhler H. GABAA receptor diversity and pharmacology. Cell Tissue Res. 2006 Nov;326(2):505–16.

  21. Paton C. Benzodiazepines and disinhibition: a review. The Psychiatrist. 2002;26:460–2.

  22. Lesch KP, Wolozin BL, Murphy DL, Reiderer P. Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem. 1993 Jun;60(6):2319–22.

  23. Sneddon JM. Blood platelets as a model for monoamine-containing neurones. Prog Neurobiol. 1973;1(2):151–98.

  24. Javors M, Tiouririne M, Prihoda T. Platelet serotonin uptake is higher in early-onset than in late-onset alcoholi cs. Alcohol Alcohol. 2000 Jul– Aug;35(4):390–3.

  25. Arranz B, Rosel P, Sarró S, Zaldivar E, Cano R, Navarro MA, et al. Platelet serotonergic binding sites in alcohol-dependent patients. Alcohol Alcohol. 1999 Sep–Oct;34(5):726–32.

  26. Bailly D, Vignau J, Racadot N, Beuscart R, Servant D, Parquet PJ. Platelet serotonin levels in alcoholic patients: changes related to physiological and pathological factors. Psychiatry Res. 1993 Apr;47(1):57–88.

  27. Bailly D, Vignau J, Lauth B, Racadot N, Beuscart R, Servant D, et al. Platelet serotonin decrease in alcoholic patients. Acta Psychiatr Scand. 1990 Jan;81(1):68–72.

  28. Alvarez JC, Gluck N, Arnulf I, Quintin P, Leboyer M, Pecquery R, et al. Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fl uoxetine. Clin Pharmacol Ther. 1999 Dec;66(6):617–24.

  29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. DSMIV. 4th ed. Washington: American Psychiatric Association; 2001.

  30. Easton C, Meza E, Mager D, Ulüg B, Kilic C, Gögüs A, et al. Test-retest reliability of the schedules for clinical assessment in neuropsychiatry (SCAN). Drug Alcohol Depend. 1997 Sep 25;47(3):187–94.

  31. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 1989 Nov;84(11):1353–7.

  32. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–75.

  33. Trevisan L, Boutros N, Petrakis IL, Krystal JH. Complications of alcohol withdrawal, pathophysiological insights. Alcohol Health & Res World. 1998;22(1):61–6.

  34. Ruusa J, Bergman B. Sex hormones and alcohol withdrawal: does a good supply of testosterone prevent serious symptoms during detoxifi cation?Alcohol. 1996 Mar–Apr;13(2):139–45.




2020     |     www.medigraphic.com